Download PDFPDF
The utility of the Cambridge Behavioural Inventory in neurodegenerative disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    The utility of the Cambridge Behavioural Inventory in neurodegenerative disease
    • Andrew J Larner, Consultant Neurologist
    • Other Contributors:
      • Pavla Hancock, Brooker Centre, Runcorn

    Dear Editor

    Like Dr Wedderburn and colleagues,1 we have investigated the clinical utility of the Cambridge Behavioural Inventory (CBI), but in patients attending memory clinics and not preselected for clinical diagnosis. This pragmatic approach has shown that the difference in CBI global score (possible range 0-324) between patients diagnosed with dementia (range 20-239, mean 99.3 +/- 54.0) and without dementia...

    Show More
    Conflict of Interest:
    None declared.